BSA204
/ Bisirna Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 20, 2026
Safety, PK, and PD of BSA204 in Chinese Adults With Borderline Elevated Lipoprotein(a)
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Dyslipidemia • Metabolic Disorders
1 to 1
Of
1
Go to page
1